DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Deksmedetomidine and Remifentanil in Extubation Agitation

Information source: Diskapi Yildirim Beyazit Education and Research Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Agitation

Intervention: deksmedetomidine (Drug); Remifentanil (Drug); Saline (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Diskapi Yildirim Beyazit Education and Research Hospital

Official(s) and/or principal investigator(s):
Reyhan Polat, MD, Principal Investigator, Affiliation: Yildirim Beyazit Education and Research Hospita

Overall contact:
Reyhan Polat, MD, Phone: +905326734310, Email: reyhanp9@gmail.com


To compare the effect of two different agents deksmedetomidine, remifentanil and placebo, agitation and recovery condition, on nasal septum operation.

Clinical Details

Official title: The Effect of Deksmedetomidin and Remifentanil Infusion on Extubation Agitation and Recovery Conditions on Nasal Septoplasty Operation

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: To asses postoperative agitation score by Riker sedation agitation scale

Secondary outcome: Yo asses postoperative side effects emesis, vomitting or pain

Detailed description: Nasal septum operation cause agitation because of nasal package. This research aims determine which agent , deksmedetomidine remifentanil or placebo, is more beneficial to the patient.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Adult patients

Exclusion Criteria:

- patients with any sensitivity each drug

Locations and Contacts

Reyhan Polat, MD, Phone: +905326734310, Email: reyhanp9@gmail.com

Reyhan Polat, Ankara 06610, Turkey; Not yet recruiting
Reyhan Polat, MD, Phone: +905326734310, Email: reyhanp9@gmail.com
Reyhan Polat, MD, Principal Investigator
Additional Information

Starting date: April 2014
Last updated: April 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017